Oncology Publications

The publications listed below are offered for informational purposes only and do not represent all publications to which X4 Pharmaceuticals or its collaboration partners have contributed or may contribute or that relate to X4 Pharmaceuticals’ product candidates.  These publications are made available by third parties, and the content of any linked third-party site is the responsibility of the third party, not X4 Pharmaceuticals, and X4 Pharmaceuticals disclaims liability for the linked content.


Journal of Clinical Oncology, 38(11), 1198-1208. doi:10.1200/jco.19.02314

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. 

Steven P. Treon, MD, PhD1,2Lian Xu, MS1Maria Luisa Guerrera, MD1,2Cristina Jimenez, PhD1,2Zachary R. Hunter, PhD1,2Xia Liu, MD1,2Maria Demos, BS1Joshua Gustine, MPH1Gloria Chan, MS1Manit Munshi, MS1Nicholas Tsakmaklis, BA1Jiaji G. Chen, BS1Amanda Kofides, BS1Romanos Sklavenitis-Pistofidis, MD2,3,4Mark Bustoros, MD2,3Andrew Keezer, BS1Kirsten Meid, MPH1Christopher J. Patterson, MAcc, MPH1Antonio Sacco, RN3,4Aldo Roccaro, MD, PhD4Andrew R. Branagan, MD5Guang Yang, PhD1,2Irene M. Ghobrial, MD2,3; and Jorge J. Castillo, MD1,2


Expert Rev Hematol. 2019 Jul 30:1-9. doi: 10.1080/17474086.2019.1649132. [Epub ahead of print]

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.

Castillo JJ1Moreno DF2Arbelaez MI3Hunter ZR1Treon SP1.


Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16088. [Epub ahead of print]

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.

Castillo JJ1,2, Xu L1, Gustine JN1,3, Keezer A1, Meid K1, Dubeau TE1, Liu X1, Demos MG1, Kofides A1, Tsakmaklis N1, Chen JG1, Munshi M1, Guerrera ML1, Chan GG1, Patterson CJ1, Yang G1,2, Hunter ZR1, Treon SP1,2.


Br J Haematol. 2015 Mar;168(5):701-7. doi: 10.1111/bjh.13200. Epub 2014 Nov 5.

CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.

Cao Y1Hunter ZRLiu XXu LYang GChen JTsakmaklis NKanan SCastillo JJTreon SP.


Leukemia. 2015 Jan;29(1):169-76. doi: 10.1038/leu.2014.187. Epub 2014 Jun 10.

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia.


Blood. 2014 Jun 26;123(26):4120-31. doi: 10.1182/blood-2014-03-564583. Epub 2014 Apr 7.

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.

Roccaro AM1Sacco A1Jimenez C2Maiso P1Moschetta M1Mishima Y1Aljawai Y1Sahin I1Kuhne M3Cardarelli P3Cohen L4San Miguel JF5Garcia-Sanz R2Ghobrial IM1.
Author information

CXCR4 General: Tumor Microenvironment

Clin Cancer Res. 2015 Oct 1;21(19):4278-85. doi: 10.1158/1078-0432.CCR-14-0914. Epub 2015 Jul 21.

Molecular Pathways: Targeting the CXCR4-CXCL12 Axis–Untapped Potential in the Tumor Microenvironment.


Oncotarget. 2017 Aug 19;8(44):77110-77120. doi: 10.18632/oncotarget.20363. eCollection 2017 Sep 29.

Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.

Santagata S1Napolitano M1D’Alterio C1Desicato S2Maro SD3Marinelli L3Fragale A4Buoncervello M4Persico F5Gabriele L4Novellino E3Longo N5Pignata S2Perdonà S2Scala S1.


Curr Cancer Drug Targets. 2012 Jul;12(6):693-702.

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

D’ Alterio C1, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.
Author information
Department of Oncological Immunology, Istituto per lo Studio e la Cura dei Tumori “Pascale”, Naples, Italy.


Nat Med. 2013 Jan;19(1):50-6. doi: 10.1038/nm.3029. Epub 2012 Dec 9.

Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Vanharanta S1, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J.
Author information
Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.


Nature. 2003 Sep 18;425(6955):307-11.

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

Staller P1Sulitkova JLisztwan JMoch HOakeley EJKrek W.

X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.